This is a scientific update with no new binary catalyst, the Phase 2b data readouts in mid-2027 and late 2027 are the next major value inflection points. Monitor for any early efficacy signals or safety flags from the ongoing trials, but no immediate trading action is warranted.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 15 $82.21entry
- T+1 · 6mo ago −3.09%α −3.03% · $79.67
- T+5 · 6mo ago −4.04%α −5.00% · $78.89
- T+20 · 5mo ago +4.11%α +1.99% · $85.59
- T+60 · 3mo ago +33.34%α +28.83% · $109.62
Price Chart
How similar events traded
Executive Summary
Kymera Therapeutics announced that KT-621 Phase 1b atopic dermatitis data will be presented at SID and ATS conferences, showing deep STAT6 degradation in skin, biomarker reductions, and clinical activity. Parallel Phase 2b trials in AD and asthma are ongoing with data expected by mid-2027 and late 2027, respectively. The press release contains no new financial data or regulatory milestones, it is a routine scientific update.
Key Facts
- KT-621 Phase 1b data featured in late-breaking oral presentation at SID 2026 (May 16) and oral presentation at ATS Respiratory Innovation Summit (May 16).
- New immunohistochemistry data show robust STAT6 degradation in epidermal keratinocytes and dermis after 4 weeks of treatment.
- Transcriptomic analyses revealed downregulation of AD-relevant gene signatures including Type 2 markers, epithelial hyperplasia, itch signaling, fibrosis, and broader inflammatory pathways.
- Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing, with data expected by mid-2027 and late 2027, respectively.
- KT-621 is a first-in-class oral STAT6 degrader targeting IL-4/IL-13 signaling, the central driver of Type 2 inflammation.
Financial Impact
No financial data or guidance provided; pre-revenue clinical-stage company.
Risk Factors
- Phase 2b results may not replicate Phase 1b efficacy or safety profile.
- Competition from existing biologics (dupilumab) and other oral therapies in development for Type 2 inflammatory diseases.
- Clinical-stage biotech with no approved products or revenue; reliance on capital markets for funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295720 |
Track record
37 reports on KYMR
7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers